{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:55:03Z","timestamp":1791467703295,"version":"4.3.4"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03459-4","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:02:42Z","timestamp":1791460962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Breaking adaptive oncogenic resistance in glioblastoma via targeting the EGFR\u2013STAT3 axis"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9187-1183","authenticated-orcid":false,"given":"Nisar","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arfan","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"3459_CR1","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ccell.2021.01.006","volume":"39","author":"L-B Wang","year":"2021","unstructured":"Wang L-B, Karpova A, Gritsenko MA, Kyle JE, Cao S, Li Y, et al. Proteogenomic and metabolomic characterization of human glioblastoma. Cancer Cell. 2021;39:509\u201328. e20.","journal-title":"Cancer Cell"},{"key":"3459_CR2","doi-asserted-by":"publisher","first-page":"e00431","DOI":"10.1016\/j.neurot.2024.e00431","volume":"21","author":"N Ahmad","year":"2024","unstructured":"Ahmad N, Chen L, Yuan Z, Ma X, Yang X, Wang Y, et al. Pyrimidine compounds BY4003 and BY4008 inhibit glioblastoma cells growth via modulating JAK3\/STAT3 signaling pathway. Neurotherapeutics. 2024;21:e00431.","journal-title":"Neurotherapeutics"},{"key":"3459_CR3","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1186\/s12967-025-07216-5","volume":"23","author":"MR Blomquist","year":"2025","unstructured":"Blomquist MR, Noviello TM, Sereduk C, Grief D, Caruso FP, Sharma R, et al. Glioblastoma resistance to EGFR antibody-drug conjugate is driven by transcriptional reprogramming and TEK-induced EGFR suppression. J translational Med. 2025;23:1153.","journal-title":"J translational Med"},{"key":"3459_CR4","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.3390\/cells10071783","volume":"10","author":"A Carrano","year":"2021","unstructured":"Carrano A, Juarez JJ, Incontri D, Ibarra A, Cazares HG. Sex-specific differences in glioblastoma. Cells. 2021;10:1783.","journal-title":"Cells"},{"key":"3459_CR5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","volume":"19","author":"AJ Cooper","year":"2022","unstructured":"Cooper AJ, Sequist LV, Lin JJ. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat Reviews Clin Oncol. 2022;19:499\u2013514.","journal-title":"Nat Reviews Clin Oncol"},{"key":"3459_CR6","doi-asserted-by":"publisher","first-page":"1236246","DOI":"10.3389\/fonc.2023.1236246","volume":"13","author":"X-P Li","year":"2023","unstructured":"Li X-P, Guo Z-Q, Wang B-F, Zhao M. EGFR alterations in glioblastoma play a role in antitumor immunity regulation. Front Oncol. 2023;13:1236246.","journal-title":"Front Oncol"},{"key":"3459_CR7","doi-asserted-by":"crossref","unstructured":"Lee M, Rous FA, Borczuk A, Liu S, Gadgeel S, Halmos B. Targeting Oncogenic Driver Mutations in Lung Cancer. Cambridge University Press; 2023.","DOI":"10.1017\/9781009336123"},{"key":"3459_CR8","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1038\/s41556-022-00962-4","volume":"24","author":"G Guo","year":"2022","unstructured":"Guo G, Gong K, Beckley N, Zhang Y, Yang X, Chkheidze R, et al. EGFR ligand shifts the role of EGFR from oncogene to tumour suppressor in EGFR-amplified glioblastoma by suppressing invasion through BIN3 upregulation. Nat Cell Biol. 2022;24:1291\u2013305.","journal-title":"Nat Cell Biol"},{"key":"3459_CR9","doi-asserted-by":"publisher","first-page":"1098482","DOI":"10.3389\/fcell.2023.1098482","volume":"11","author":"W Fu","year":"2023","unstructured":"Fu W, Hou X, Dong L, Hou W. Roles of STAT3 in the pathogenesis and treatment of glioblastoma. Front cell Dev biology. 2023;11:1098482.","journal-title":"Front cell Dev biology"},{"key":"3459_CR10","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.3390\/cancers14102412","volume":"14","author":"S Grochans","year":"2022","unstructured":"Grochans S, Cybulska AM, Simi\u0144ska D, Korbecki J, Kojder K, Chlubek D, et al. Epidemiology of glioblastoma multiforme\u2013literature review. Cancers. 2022;14:2412.","journal-title":"Cancers"},{"key":"3459_CR11","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3390\/cancers13030437","volume":"13","author":"A Ou","year":"2021","unstructured":"Ou A, Ott M, Fang D, Heimberger AB. The role and therapeutic targeting of JAK\/STAT signaling in glioblastoma. Cancers. 2021;13:437.","journal-title":"Cancers"},{"key":"3459_CR12","doi-asserted-by":"publisher","first-page":"11110","DOI":"10.3390\/ijms241311110","volume":"24","author":"SMB Rodriguez","year":"2023","unstructured":"Rodriguez SMB, Kamel A, Ciubotaru GV, Onose G, Sevastre A-S, Sfredel V, et al. An overview of EGFR mechanisms and their implications in targeted therapies for glioblastoma. Int J Mol Sci. 2023;24:11110.","journal-title":"Int J Mol Sci"},{"key":"3459_CR13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.pccm.2026.05.003","volume":"4","author":"Z Xu","year":"2026","unstructured":"Xu Z, Huang S, Chu Q. Molecular mechanisms and therapeutic targets in lung cancer\u2013nerve crosstalk. Chin Med J Pulmonary Crit Care Med. 2026;4:117\u201336.","journal-title":"Chin Med J Pulmonary Crit Care Med"},{"key":"3459_CR14","first-page":"1231","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neurooncology. 2021;23:1231\u201351.","journal-title":"Neurooncology"},{"key":"3459_CR15","first-page":"59","volume":"21","author":"AK Park","year":"2019","unstructured":"Park AK, Kim P, Ballester LY, Esquenazi Y, Zhao Z. Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma. Neurooncology. 2019;21:59\u201370.","journal-title":"Neurooncology"},{"key":"3459_CR16","doi-asserted-by":"publisher","first-page":"873042","DOI":"10.3389\/fmolb.2022.873042","volume":"9","author":"H Jin","year":"2022","unstructured":"Jin H, Yu Z, Tian T, Shen G, Chen W, Fan M, et al. Integrative genomic and transcriptomic analysis of primary malignant gliomas revealed different patterns between grades and somatic mutations related to glioblastoma prognosis. Front Mol Biosci. 2022;9:873042.","journal-title":"Front Mol Biosci"},{"key":"3459_CR17","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.3390\/brainsci13121700","volume":"13","author":"C Toader","year":"2023","unstructured":"Toader C, Eva L, Costea D, Corlatescu AD, Covache-Busuioc R-A, Bratu B-G, et al. Low-grade gliomas: histological subtypes, molecular mechanisms, and treatment strategies. Brain Sci. 2023;13:1700.","journal-title":"Brain Sci"},{"key":"3459_CR18","doi-asserted-by":"publisher","first-page":"vdad009","DOI":"10.1093\/noajnl\/vdad009","volume":"5","author":"P Sharma","year":"2023","unstructured":"Sharma P, Aaroe A, Liang J, Puduvalli VK. Tumor microenvironment in glioblastoma: Current and emerging concepts. Neuro-oncology Adv. 2023;5:vdad009.","journal-title":"Neuro-oncology Adv"},{"key":"3459_CR19","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/s41416-022-01864-w","volume":"127","author":"KJ Habashy","year":"2022","unstructured":"Habashy KJ, Mansour R, Moussalem C, Sawaya R, Massaad MJ. Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them. Br J Cancer. 2022;127:976\u201387.","journal-title":"Br J Cancer"},{"key":"3459_CR20","doi-asserted-by":"publisher","first-page":"vdaa020","DOI":"10.1093\/noajnl\/vdaa020","volume":"2","author":"KV Jensen","year":"2020","unstructured":"Jensen KV, Hao X, Aman A, Luchman HA, Weiss S. EGFR blockade in GBM brain tumor stem cells synergizes with JAK2\/STAT3 pathway inhibition to abrogate compensatory mechanisms in vitro and in vivo. Neuro-oncology Adv. 2020;2:vdaa020.","journal-title":"Neuro-oncology Adv"},{"key":"3459_CR21","doi-asserted-by":"publisher","first-page":"108118","DOI":"10.1016\/j.pharmthera.2022.108118","volume":"234","author":"P-C Shih","year":"2022","unstructured":"Shih P-C. The role of the STAT3 signaling transduction pathways in radioresistance. Pharmacol Ther. 2022;234:108118.","journal-title":"Pharmacol Ther"},{"key":"3459_CR22","doi-asserted-by":"publisher","unstructured":"Khan F, Pang L, Dunterman M, Lesniak MS, Heimberger AB, Chen P. Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy. J Clin Investig. 2023;133. https:\/\/doi.org\/10.1172\/JCI163446.","DOI":"10.1172\/JCI163446"},{"key":"3459_CR23","doi-asserted-by":"publisher","first-page":"8261","DOI":"10.3390\/ijms21218261","volume":"21","author":"A Ja\u015bkiewicz","year":"2020","unstructured":"Ja\u015bkiewicz A, Domoradzki T, Paj\u0105k B. Targeting the JAK2\/STAT3 pathway\u2014Can we compare it to the two faces of the God Janus? Int J Mol Sci. 2020;21:8261.","journal-title":"Int J Mol Sci"},{"key":"3459_CR24","doi-asserted-by":"publisher","first-page":"440","DOI":"10.2174\/1871520622666220609112816","volume":"23","author":"T Wu","year":"2023","unstructured":"Wu T, Yu J, Wang C, Jin Y, Zheng X, Chen L, et al. Novel potent EGFR-JAK3 dual-target inhibitor that overcomes KRAS mutation resistance in colorectal cancer. Anti-Cancer Agents Med Chemistry-Anti-Cancer Agents. 2023;23:440\u20139.","journal-title":"Anti-Cancer Agents Med Chemistry-Anti-Cancer Agents"},{"key":"3459_CR25","doi-asserted-by":"publisher","first-page":"1434495","DOI":"10.3389\/fonc.2024.1434495","volume":"14","author":"RC Sterner","year":"2024","unstructured":"Sterner RC, Sterner RM. EGFRVIII and EGFR targeted chimeric antigen receptor T cell therapy in glioblastoma. Front Oncol. 2024;14:1434495.","journal-title":"Front Oncol"},{"key":"3459_CR26","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41392-022-01168-8","volume":"7","author":"Y Yang","year":"2022","unstructured":"Yang Y, Li S, Wang Y, Zhao Y, Li Q. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. Signal Transduct Target therapy. 2022;7:329.","journal-title":"Signal Transduct Target therapy"},{"key":"3459_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-019-1035-0","volume":"38","author":"PP Vitiello","year":"2019","unstructured":"Vitiello PP, Cardone C, Martini G, Ciardiello D, Belli V, Matrone N, et al. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR\/RAS\/MAPK pathway in KRAS-mutated human colorectal cancer cell lines. J Experimental Clin Cancer Res. 2019;38:1\u201312.","journal-title":"J Experimental Clin Cancer Res"},{"key":"3459_CR28","doi-asserted-by":"crossref","unstructured":"Tewari D, Patni P, Bishayee A, Sah AN, Bishayee A. Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy. Seminars in cancer biology. Elsevier; 2022. pp. 1\u201317.","DOI":"10.1016\/j.semcancer.2019.12.008"},{"key":"3459_CR29","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.3390\/cancers13143517","volume":"13","author":"H Li","year":"2021","unstructured":"Li H, Prever L, Hirsch E, Gulluni F. Targeting PI3K\/AKT\/mTOR signaling pathway in breast cancer. Cancers. 2021;13:3517.","journal-title":"Cancers"},{"key":"3459_CR30","doi-asserted-by":"publisher","first-page":"10132","DOI":"10.3390\/ijms231710132","volume":"23","author":"S Stanciu","year":"2022","unstructured":"Stanciu S, Ionita-Radu F, Stefani C, Miricescu D, Stanescu-Spinu I-I, Greabu M, et al. Targeting PI3K\/AKT\/mTOR signaling pathway in pancreatic cancer: from molecular to clinical aspects. Int J Mol Sci. 2022;23:10132.","journal-title":"Int J Mol Sci"},{"key":"3459_CR31","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","volume":"8","author":"ME Bahar","year":"2023","unstructured":"Bahar ME, Kim HJ, Kim DR. Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduct Target therapy. 2023;8:455.","journal-title":"Signal Transduct Target therapy"},{"key":"3459_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s43556-022-00110-2","volume":"3","author":"Q Li","year":"2022","unstructured":"Li Q, Li Z, Luo T, Shi H. Targeting the PI3K\/AKT\/mTOR and RAF\/MEK\/ERK pathways for cancer therapy. Mol Biomed. 2022;3:47.","journal-title":"Mol Biomed"},{"key":"3459_CR33","doi-asserted-by":"publisher","first-page":"798","DOI":"10.3390\/biom13050798","volume":"13","author":"MV Marvi","year":"2023","unstructured":"Marvi MV, Neri I, Evangelisti C, Ramazzotti G, Asioli S, Zoli M, et al. Phospholipases in Gliomas: Current Knowledge and Future Perspectives from Bench to Bedside. Biomolecules. 2023;13:798.","journal-title":"Biomolecules"},{"key":"3459_CR34","doi-asserted-by":"publisher","first-page":"2226418","DOI":"10.1080\/15384047.2023.2226418","volume":"24","author":"L Huang","year":"2023","unstructured":"Huang L, Zhao Y, Shan M, Wang S, Chen J, Liu Z, et al. Targeting crosstalk of STAT3 between tumor-associated M2 macrophages and Tregs in colorectal cancer. Cancer Biol Ther. 2023;24:2226418.","journal-title":"Cancer Biol Ther"},{"key":"3459_CR35","doi-asserted-by":"publisher","first-page":"105164","DOI":"10.1016\/j.phrs.2020.105164","volume":"161","author":"Y Liang","year":"2020","unstructured":"Liang Y, Zhang T, Zhang J. Natural tyrosine kinase inhibitors acting on the epidermal growth factor receptor: Their relevance for cancer therapy. Pharmacol Res. 2020;161:105164.","journal-title":"Pharmacol Res"},{"key":"3459_CR36","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.3390\/ijms21061960","volume":"21","author":"L Ding","year":"2020","unstructured":"Ding L, Cao J, Lin W, Chen H, Xiong X, Ao H, et al. The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer. Int J Mol Sci. 2020;21:1960.","journal-title":"Int J Mol Sci"},{"key":"3459_CR37","doi-asserted-by":"publisher","first-page":"140025","DOI":"10.1016\/j.ijbiomac.2025.140025","volume":"298","author":"A-I B\u0103r\u0103ian","year":"2025","unstructured":"B\u0103r\u0103ian A-I, Raduly L, Z\u0103noag\u0103 O, Iacob B-C, Barbu-Tudoran L, Dinte E, et al. Targeting JAK\/STAT3 in glioblastoma cells using an alginate-PNIPAm molecularly imprinted hydrogel for the sustained release of ruxolitinib. Int J Biol Macromol. 2025;298:140025.","journal-title":"Int J Biol Macromol"},{"key":"3459_CR38","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1080\/15384047.2022.2051158","volume":"23","author":"H Gao","year":"2022","unstructured":"Gao H, Wang W, Li Q. GANT61 suppresses cell survival, invasion and epithelial-mesenchymal transition through inactivating AKT\/mTOR and JAK\/STAT3 pathways in anaplastic thyroid carcinoma. Cancer Biol Ther. 2022;23:369\u201377.","journal-title":"Cancer Biol Ther"},{"key":"3459_CR39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12964-020-0527-z","volume":"18","author":"J-h Ma","year":"2020","unstructured":"Ma J-h, Qin L, Li X. Role of STAT3 signaling pathway in breast cancer. Cell Communication Signal. 2020;18:33.","journal-title":"Cell Communication Signal"},{"key":"3459_CR40","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3390\/ijms22020603","volume":"22","author":"M Tolomeo","year":"2021","unstructured":"Tolomeo M, Cascio A. The multifaced role of STAT3 in cancer and its implication for anticancer therapy. Int J Mol Sci. 2021;22:603.","journal-title":"Int J Mol Sci"},{"key":"3459_CR41","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.1097\/MS9.0000000000003411","volume":"87","author":"EI Obeagu","year":"2025","unstructured":"Obeagu EI. Hypoxia-driven angiogenesis in breast cancer mechanisms and therapeutic targets: a narrative review. Annals Med Surg. 2025;87:4246\u201354.","journal-title":"Annals Med Surg"},{"key":"3459_CR42","doi-asserted-by":"publisher","first-page":"107969","DOI":"10.1016\/j.pharmthera.2021.107969","volume":"230","author":"L Zhang","year":"2022","unstructured":"Zhang L, Kuca K, You L, Zhao Y, Musilek K, Nepovimova E, et al. Signal transducer and activator of transcription 3 signaling in tumor immune evasion. Pharmacol Ther. 2022;230:107969.","journal-title":"Pharmacol Ther"},{"key":"3459_CR43","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.3390\/cells11162618","volume":"11","author":"S Hashimoto","year":"2022","unstructured":"Hashimoto S, Hashimoto A, Muromoto R, Kitai Y, Oritani K, Matsuda T. Central roles of STAT3-mediated signals in onset and development of cancers: tumorigenesis and immunosurveillance. Cells. 2022;11:2618.","journal-title":"Cells"},{"key":"3459_CR44","doi-asserted-by":"publisher","unstructured":"Zheng J, Jiang J, Pu Y, Xu T, Sun J, Zhang Q et al. Tumor-associated macrophages in nanomaterial-based anti-tumor therapy: as target spots or delivery platforms. Front Bioeng Biotechnol. 2023;11. https:\/\/doi.org\/10.3389\/fbioe.2023.1248421.","DOI":"10.3389\/fbioe.2023.1248421"},{"key":"3459_CR45","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12964-021-00705-2","volume":"19","author":"J Jin","year":"2021","unstructured":"Jin J, Li Y, Zhao Q, Chen Y, Fu S, Wu J. Coordinated regulation of immune contexture: crosstalk between STAT3 and immune cells during breast cancer progression. Cell Communication Signal. 2021;19:50.","journal-title":"Cell Communication Signal"},{"key":"3459_CR46","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.3390\/cancers12092459","volume":"12","author":"P-L Yang","year":"2020","unstructured":"Yang P-L, Liu L-X, Li E-M, Xu L-Y. STAT3, the challenge for chemotherapeutic and radiotherapeutic efficacy. Cancers. 2020;12:2459.","journal-title":"Cancers"},{"key":"3459_CR47","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/cells9010217","volume":"9","author":"W Jin","year":"2020","unstructured":"Jin W. Role of JAK\/STAT3 signaling in the regulation of metastasis, the transition of cancer stem cells, and chemoresistance of cancer by epithelial\u2013mesenchymal transition. Cells. 2020;9:217.","journal-title":"Cells"},{"key":"3459_CR48","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41392-020-00430-1","volume":"6","author":"H-M Zhou","year":"2021","unstructured":"Zhou H-M, Zhang J-G, Zhang X, Li Q. Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents. Signal Transduct Target therapy. 2021;6:62.","journal-title":"Signal Transduct Target therapy"},{"key":"3459_CR49","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.3390\/cancers14102416","volume":"14","author":"JB Vilar","year":"2022","unstructured":"Vilar JB, Christmann M, Tomicic MT. Alterations in molecular profiles affecting glioblastoma resistance to radiochemotherapy: where does the good go? Cancers. 2022;14:2416.","journal-title":"Cancers"},{"key":"3459_CR50","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.3390\/cells10071610","volume":"10","author":"L Gai","year":"2021","unstructured":"Gai L, Zhu Y, Zhang C, Meng X. Targeting canonical and non-canonical STAT signaling pathways in renal diseases. Cells. 2021;10:1610.","journal-title":"Cells"},{"key":"3459_CR51","doi-asserted-by":"publisher","unstructured":"Song X, Liu Z, Yu Z. EGFR promotes the development of triple negative breast cancer through JAK\/STAT3 signaling. Cancer Manage Res. 2020:703\u201317. https:\/\/doi.org\/10.2147\/CMAR.S225376.","DOI":"10.2147\/CMAR.S225376"},{"key":"3459_CR52","doi-asserted-by":"publisher","first-page":"12828","DOI":"10.3390\/ijms222312828","volume":"22","author":"W-L Cheng","year":"2021","unstructured":"Cheng W-L, Feng P-H, Lee K-Y, Chen K-Y, Sun W-L, Van Hiep N, et al. The role of EREG\/EGFR pathway in tumor progression. Int J Mol Sci. 2021;22:12828.","journal-title":"Int J Mol Sci"},{"key":"3459_CR53","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41568-018-0090-8","volume":"19","author":"J Huynh","year":"2019","unstructured":"Huynh J, Chand A, Gough D, Ernst M. Therapeutically exploiting STAT3 activity in cancer\u2014using tissue repair as a road map. Nat Rev Cancer. 2019;19:82\u201396.","journal-title":"Nat Rev Cancer"},{"key":"3459_CR54","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O\u2019Keefe RA, Grandis JR. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat reviews Clin Oncol. 2018;15:234\u201348.","journal-title":"Nat reviews Clin Oncol"},{"key":"3459_CR55","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/14728222.2023.2218613","volume":"27","author":"S Halder","year":"2023","unstructured":"Halder S, Basu S, Lall SP, Ganti AK, Batra SK, Seshacharyulu P. Targeting the EGFR signaling pathway in cancer therapy: What\u2019s new in 2023? Expert Opin Ther Targets. 2023;27:305\u201324.","journal-title":"Expert Opin Ther Targets"},{"key":"3459_CR56","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3390\/pharmaceutics14051001","volume":"14","author":"AM Shawky","year":"2022","unstructured":"Shawky AM, Almalki FA, Abdalla AN, Abdelazeem AH, Gouda AM. A comprehensive overview of globally approved JAK inhibitors. Pharmaceutics. 2022;14:1001.","journal-title":"Pharmaceutics"},{"key":"3459_CR57","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.3390\/cancers15143722","volume":"15","author":"S Khalili","year":"2023","unstructured":"Khalili S, Zeinali F, Moghadam Fard A, Taha SR, Fazlollahpour Naghibi A, Bagheri K, et al. Macrophage-Based Therapeutic Strategies in Hematologic Malignancies. Cancers. 2023;15:3722.","journal-title":"Cancers"},{"key":"3459_CR58","doi-asserted-by":"publisher","first-page":"21","DOI":"10.20892\/j.issn.2095-3941.2020.0150","volume":"18","author":"C He","year":"2021","unstructured":"He C, Li L, Wang L, Meng W, Hao Y, Zhu G. Exosome-mediated cellular crosstalk within the tumor microenvironment upon irradiation. Cancer biology Med. 2021;18:21\u201333.","journal-title":"Cancer biology Med"},{"key":"3459_CR59","doi-asserted-by":"publisher","first-page":"101549","DOI":"10.1016\/j.adro.2024.101549","volume":"9","author":"S Yu","year":"2024","unstructured":"Yu S, Jiang S, Zhou Y, Zhu Z, Yang X. Impact of radiation on exosomes in regulating tumor immune microenvironment. Adv Radiation Oncol. 2024;9:101549.","journal-title":"Adv Radiation Oncol"},{"key":"3459_CR60","first-page":"17","volume":"4","author":"N Singh","year":"2021","unstructured":"Singh N, Miner A, Hennis L, Mittal S. Mechanisms of temozolomide resistance in glioblastoma-a comprehensive review. Cancer drug Resist. 2021;4:17.","journal-title":"Cancer drug Resist"},{"key":"3459_CR61","doi-asserted-by":"publisher","first-page":"109598","DOI":"10.1016\/j.cellsig.2020.109598","volume":"71","author":"P Cui","year":"2020","unstructured":"Cui P, Wei F, Hou J, Su Y, Wang J, Wang S. STAT3 inhibition induced temozolomide-resistant glioblastoma apoptosis via triggering mitochondrial STAT3 translocation and respiratory chain dysfunction. Cell Signal. 2020;71:109598.","journal-title":"Cell Signal"},{"key":"3459_CR62","doi-asserted-by":"publisher","first-page":"8471","DOI":"10.3390\/ijms21228471","volume":"21","author":"PC Pan","year":"2020","unstructured":"Pan PC, Magge RS. Mechanisms of EGFR resistance in glioblastoma. Int J Mol Sci. 2020;21:8471.","journal-title":"Int J Mol Sci"},{"key":"3459_CR63","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.3390\/cells8111398","volume":"8","author":"C Piperi","year":"2019","unstructured":"Piperi C, Papavassiliou KA, Papavassiliou AG. Pivotal role of STAT3 in shaping glioblastoma immune microenvironment. Cells. 2019;8:1398.","journal-title":"Cells"},{"key":"3459_CR64","doi-asserted-by":"publisher","first-page":"1248421","DOI":"10.3389\/fbioe.2023.1248421","volume":"11","author":"J Zheng","year":"2023","unstructured":"Zheng J, Jiang J, Pu Y, Xu T, Sun J, Zhang Q, et al. Tumor-associated macrophages in nanomaterial-based anti-tumor therapy: as target spots or delivery platforms. Front Bioeng Biotechnol. 2023;11:1248421.","journal-title":"Front Bioeng Biotechnol"},{"key":"3459_CR65","doi-asserted-by":"publisher","first-page":"604","DOI":"10.4252\/wjsc.v16.i5.604","volume":"16","author":"E Agosti","year":"2024","unstructured":"Agosti E, Zeppieri M, Ghidoni M, Ius T, Tel A, Fontanella MM, et al. Role of glioma stem cells in promoting tumor chemo-and radioresistance: A systematic review of potential targeted treatments. World J Stem Cells. 2024;16:604.","journal-title":"World J Stem Cells"},{"key":"3459_CR66","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3390\/cells12020276","volume":"12","author":"A Mamilos","year":"2023","unstructured":"Mamilos A, Winter L, Schmitt VH, Barsch F, Grevenstein D, Wagner W, et al. Macrophages: from simple phagocyte to an integrative regulatory cell for inflammation and tissue regeneration\u2014a review of the literature. Cells. 2023;12:276.","journal-title":"Cells"},{"key":"3459_CR67","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.biopha.2018.05.079","volume":"104","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Jin G, Zhang J, Mi R, Zhou Y, Fan W, et al. Overexpression of STAT1 suppresses angiogenesis under hypoxia by regulating VEGF\u2013A in human glioma cells. Biomed Pharmacother. 2018;104:566\u201375.","journal-title":"Biomed Pharmacother"},{"key":"3459_CR68","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.3390\/cancers15092613","volume":"15","author":"T Shi","year":"2023","unstructured":"Shi T, Zhu J, Zhang X, Mao X. The role of hypoxia and cancer stem cells in development of glioblastoma. Cancers. 2023;15:2613.","journal-title":"Cancers"},{"key":"3459_CR69","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41392-021-00693-2","volume":"6","author":"Y Niu","year":"2021","unstructured":"Niu Y, Mayr T, Muders MH. Competition for nutrients or cell intrinsic programming?\u2013Metabolic mechanisms behind the tumor promoting immune microenvironment in cancer. Signal Transduct Target Therapy. 2021;6:279.","journal-title":"Signal Transduct Target Therapy"},{"key":"3459_CR70","doi-asserted-by":"publisher","first-page":"565631","DOI":"10.3389\/fimmu.2020.565631","volume":"11","author":"E Ponterio","year":"2020","unstructured":"Ponterio E, De Maria R, Haas TL. Identification of targets to redirect CAR T cells in glioblastoma and colorectal cancer: an arduous venture. Front Immunol. 2020;11:565631.","journal-title":"Front Immunol"},{"key":"3459_CR71","doi-asserted-by":"publisher","first-page":"1151862","DOI":"10.3389\/fonc.2023.1151862","volume":"13","author":"N-S Chang","year":"2023","unstructured":"Chang N-S, To KK, Liou Y-C, Li Y-J. The role of STAT3 signaling pathway in tumor progression. Front Oncol. 2023;13:1151862.","journal-title":"Front Oncol"},{"key":"3459_CR72","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s10555-017-9687-8","volume":"36","author":"MJ Xu","year":"2017","unstructured":"Xu MJ, Johnson DE, Grandis JR. EGFR-targeted therapies in the post-genomic era. Cancer Metastasis Rev. 2017;36:463\u201373.","journal-title":"Cancer Metastasis Rev"},{"key":"3459_CR73","doi-asserted-by":"publisher","unstructured":"GM, ZY, WM, PH, HM. Improving the efficacy of anti-EGFR drugs in GBM: Where we are going? Biochim et Biophys Acta (BBA)-Reviews Cancer. 2023;1878:188996. https:\/\/doi.org\/10.1016\/j.bbcan.2023.188996.","DOI":"10.1016\/j.bbcan.2023.188996"},{"key":"3459_CR74","first-page":"18","volume-title":"Nimotuzumab: beyond the EGFR signaling cascade inhibition","author":"Z Mazorra","year":"2018","unstructured":"Mazorra Z, Chao L, Lavastida A, Sanchez B, Ramos M, Iznaga N, et al. Nimotuzumab: beyond the EGFR signaling cascade inhibition. Seminars in oncology: Elsevier; 2018. pp. 18\u201326."},{"key":"3459_CR75","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/pharmaceutics15010059","volume":"15","author":"HK Brar","year":"2022","unstructured":"Brar HK, Jose J, Wu Z, Sharma M. Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery. Pharmaceutics. 2022;15:59.","journal-title":"Pharmaceutics"},{"key":"3459_CR76","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s13046-019-1264-2","volume":"38","author":"R Vengoji","year":"2019","unstructured":"Vengoji R, Macha MA, Nimmakayala RK, Rachagani S, Siddiqui JA, Mallya K, et al. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. J Experimental Clin Cancer Res. 2019;38:266.","journal-title":"J Experimental Clin Cancer Res"},{"key":"3459_CR77","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.tips.2015.10.001","volume":"37","author":"C Zhao","year":"2016","unstructured":"Zhao C, Li H, Lin H-J, Yang S, Lin J, Liang G. Feedback activation of STAT3 as a cancer drug-resistance mechanism. Trends Pharmacol Sci. 2016;37:47\u201361.","journal-title":"Trends Pharmacol Sci"},{"key":"3459_CR78","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00280-021-04369-0","volume":"89","author":"SK Padda","year":"2022","unstructured":"Padda SK, Reckamp KL, Koczywas M, Neal JW, Kawashima J, Kong S, et al. A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer. Cancer Chemother Pharmacol. 2022;89:105\u201315.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3459_CR79","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jtho.2016.08.140","volume":"12","author":"AY Helena","year":"2017","unstructured":"Helena AY, Perez L, Chang Q, Gao SP, Kris MG, Riely GJ, et al. A phase 1\/2 trial of ruxolitinib and erlotinib in patients with EGFR-mutant lung adenocarcinomas with acquired resistance to erlotinib. J Thorac Oncol. 2017;12:102\u20139.","journal-title":"J Thorac Oncol"},{"key":"3459_CR80","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.lungcan.2019.05.030","volume":"134","author":"JS Park","year":"2019","unstructured":"Park JS, Hong MH, Chun YJ, Kim HR, Cho BC. A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs. Lung Cancer. 2019;134:46\u201351.","journal-title":"Lung Cancer"},{"key":"3459_CR81","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","volume":"398","author":"DP McLornan","year":"2021","unstructured":"McLornan DP, Pope JE, Gotlib J, Harrison CN. Current and future status of JAK inhibitors. Lancet. 2021;398:803\u201316.","journal-title":"Lancet"},{"key":"3459_CR82","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","volume":"6","author":"L Zhong","year":"2021","unstructured":"Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, et al. Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives. Signal Transduct Target therapy. 2021;6:201.","journal-title":"Signal Transduct Target therapy"},{"key":"3459_CR83","doi-asserted-by":"publisher","first-page":"783067","DOI":"10.3389\/fonc.2021.783067","volume":"11","author":"M Dahlmanns","year":"2021","unstructured":"Dahlmanns M, Yakubov E, Dahlmanns JK. Genetic profiles of ferroptosis in malignant brain tumors and off-target effects of ferroptosis induction. Front Oncol. 2021;11:783067.","journal-title":"Front Oncol"},{"key":"3459_CR84","doi-asserted-by":"publisher","first-page":"vdaa124","DOI":"10.1093\/noajnl\/vdaa124","volume":"2","author":"H Chen","year":"2020","unstructured":"Chen H, Kuhn J, Lamborn KR, Abrey LE, DeAngelis LM, Lieberman F, et al. Phase I\/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05\u2009\u2013\u200902. Neuro-Oncology Adv. 2020;2:vdaa124.","journal-title":"Neuro-Oncology Adv"},{"key":"3459_CR85","doi-asserted-by":"publisher","first-page":"vdaf022","DOI":"10.1093\/noajnl\/vdaf022","volume":"7","author":"BM Ellingson","year":"2025","unstructured":"Ellingson BM, Okobi Q, Chong R, Plawat R, Zhao E, Gafita A, et al. A comparative study of preclinical and clinical molecular imaging response to EGFR Inhibition using osimertinib in glioblastoma. Neuro-Oncology Adv. 2025;7:vdaf022.","journal-title":"Neuro-Oncology Adv"},{"key":"3459_CR86","first-page":"339","volume":"25","author":"AB Lassman","year":"2023","unstructured":"Lassman AB, Pugh SL, Wang TJ, Aldape K, Gan HK, Preusser M, et al. Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial. Neurooncology. 2023;25:339\u201350.","journal-title":"Neurooncology"},{"key":"3459_CR87","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1158\/1078-0432.CCR-18-1140","volume":"26","author":"DA Reardon","year":"2020","unstructured":"Reardon DA, Desjardins A, Vredenburgh JJ, O\u2019Rourke DM, Tran DD, Fink KL, et al. Rindopepimut with bevacizumab for patients with relapsed EGFRvIII-expressing glioblastoma (ReACT): results of a double-blind randomized phase II trial. Clin Cancer Res. 2020;26:1586\u201394.","journal-title":"Clin Cancer Res"},{"key":"3459_CR88","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s12032-022-01897-4","volume":"40","author":"B Goker Bagca","year":"2022","unstructured":"Goker Bagca B, Ozates NP, Biray Avci C. Ruxolitinib enhances cytotoxic and apoptotic effects of temozolomide on glioblastoma cells by regulating WNT signaling pathway-related genes. Med Oncol. 2022;40:37.","journal-title":"Med Oncol"},{"key":"3459_CR89","doi-asserted-by":"publisher","first-page":"11401","DOI":"10.1038\/s41598-023-38629-1","volume":"13","author":"C Zhang","year":"2023","unstructured":"Zhang C, Wang Y, Shao W, Zhou D, Yu D, Hou S, et al. A novel NFAT1-IL6\/JAK\/STAT3 signaling pathway related nomogram predicts overall survival in gliomas. Sci Rep. 2023;13:11401.","journal-title":"Sci Rep"},{"key":"3459_CR90","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41419-023-06156-6","volume":"14","author":"Y Chen","year":"2023","unstructured":"Chen Y, Mu Y, Guan Q, Li C, Zhang Y, Xu Y, et al. RPL22L1, a novel candidate oncogene promotes temozolomide resistance by activating STAT3 in glioblastoma. Cell Death Dis. 2023;14:757.","journal-title":"Cell Death Dis"},{"key":"3459_CR91","doi-asserted-by":"publisher","first-page":"9453","DOI":"10.3390\/ijms24119453","volume":"24","author":"M Wu","year":"2023","unstructured":"Wu M, Song D, Li H, Ahmad N, Xu H, Yang X, et al. Resveratrol enhances temozolomide efficacy in glioblastoma cells through downregulated MGMT and negative regulators-related STAT3 inactivation. Int J Mol Sci. 2023;24:9453.","journal-title":"Int J Mol Sci"},{"key":"3459_CR92","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s00432-024-05625-5","volume":"150","author":"C Zhang","year":"2024","unstructured":"Zhang C, Peng Q, Tang Y, Wang C, Wang S, Yu D, et al. Resveratrol ameliorates glioblastoma inflammatory response by reducing NLRP3 inflammasome activation through inhibition of the JAK2\/STAT3 pathway. J Cancer Res Clin Oncol. 2024;150:168.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3459_CR93","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12943-022-01513-z","volume":"21","author":"K Yang","year":"2022","unstructured":"Yang K, Wu Z, Zhang H, Zhang N, Wu W, Wang Z, et al. Glioma targeted therapy: insight into future of molecular approaches. Mol Cancer. 2022;21:39.","journal-title":"Mol Cancer"},{"key":"3459_CR94","doi-asserted-by":"publisher","first-page":"E18761429386400","DOI":"10.2174\/0118761429386400250415053351","volume":"17","author":"G Lv","year":"2024","unstructured":"Lv G, Li X, Deng H, Zhang J, Gao X. Regulatory Mechanisms of STAT3 in GBM and its Impact on TMZ Resistance. Curr Mol Pharmacol. 2024;17:E18761429386400.","journal-title":"Curr Mol Pharmacol"},{"key":"3459_CR95","doi-asserted-by":"publisher","first-page":"4722","DOI":"10.3390\/ijms24054722","volume":"24","author":"S Singh","year":"2023","unstructured":"Singh S, Gomez HJ, Thakkar S, Singh SP, Parihar AS. Overcoming Acquired Drug Resistance to Cancer Therapies through Targeted STAT3 Inhibition. Int J Mol Sci. 2023;24:4722.","journal-title":"Int J Mol Sci"},{"key":"3459_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-018-0618-0","volume":"11","author":"H Li","year":"2018","unstructured":"Li H, Chen L, Li J-j, Zhou Q, Huang A, Liu W-w, et al. miR-519a enhances chemosensitivity and promotes autophagy in glioblastoma by targeting STAT3\/Bcl2 signaling pathway. J Hematol Oncol. 2018;11:1\u201316.","journal-title":"J Hematol Oncol"},{"key":"3459_CR97","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.3389\/fonc.2020.01120","volume":"10","author":"X Wang","year":"2020","unstructured":"Wang X, Zhang X, Qiu C, Yang N. STAT3 contributes to radioresistance in cancer. Front Oncol. 2020;10:1120.","journal-title":"Front Oncol"},{"key":"3459_CR98","doi-asserted-by":"publisher","first-page":"4983","DOI":"10.1158\/1078-0432.CCR-19-4092","volume":"26","author":"M Ott","year":"2020","unstructured":"Ott M, Kassab C, Marisetty A, Hashimoto Y, Wei J, Zamler D, et al. Radiation with STAT3 blockade triggers dendritic cell\u2013T cell interactions in the glioma microenvironment and therapeutic efficacy. Clin Cancer Res. 2020;26:4983\u201394.","journal-title":"Clin Cancer Res"},{"key":"3459_CR99","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/onc.2017.404","volume":"37","author":"D Almiron Bonnin","year":"2018","unstructured":"Almiron Bonnin D, Havrda M, Lee M, Liu H, Zhang Z, Nguyen L, et al. Secretion-mediated STAT3 activation promotes self-renewal of glioma stem-like cells during hypoxia. Oncogene. 2018;37:1107\u201318.","journal-title":"Oncogene"},{"key":"3459_CR100","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","volume":"21","author":"Y Liu","year":"2024","unstructured":"Liu Y, Zhou F, Ali H, Lathia JD, Chen P. Immunotherapy for glioblastoma: current state, challenges, and future perspectives. Cell Mol Immunol. 2024;21:1354\u201375.","journal-title":"Cell Mol Immunol"},{"key":"3459_CR101","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.3390\/cancers16071276","volume":"16","author":"I Salvato","year":"2024","unstructured":"Salvato I, Marchini A. Immunotherapeutic strategies for the treatment of glioblastoma: current challenges and future perspectives. Cancers. 2024;16:1276.","journal-title":"Cancers"},{"key":"3459_CR102","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41698-025-00920-x","volume":"9","author":"W Zhao","year":"2025","unstructured":"Zhao W, Zhang Z, Xie M, Ding F, Zheng X, Sun S, et al. Exploring tumor-associated macrophages in glioblastoma: from diversity to therapy. npj Precision Oncol. 2025;9:126.","journal-title":"npj Precision Oncol"},{"key":"3459_CR103","doi-asserted-by":"publisher","unstructured":"Zhou F, Mukherjee P, Mu J, Chen P. Therapeutic potential of targeting macrophages and microglia in glioblastoma. Trends Pharmacol Sci. 2025. https:\/\/doi.org\/10.1016\/j.tips.2025.07.006.","DOI":"10.1016\/j.tips.2025.07.006"},{"key":"3459_CR104","doi-asserted-by":"publisher","first-page":"4255","DOI":"10.3390\/cancers13174255","volume":"13","author":"RS Andersen","year":"2021","unstructured":"Andersen RS, Anand A, Harwood DSL, Kristensen BW. Tumor-associated microglia and macrophages in the glioblastoma microenvironment and their implications for therapy. Cancers. 2021;13:4255.","journal-title":"Cancers"},{"key":"3459_CR105","doi-asserted-by":"crossref","unstructured":"Cela I, Capone E, Trevisi G, Sala G. Extracellular vesicles in glioblastoma: Biomarkers and therapeutic tools. Seminars in Cancer Biology. Elsevier; 2024. pp. 25\u201343.","DOI":"10.1016\/j.semcancer.2024.04.003"},{"key":"3459_CR106","doi-asserted-by":"publisher","unstructured":"Zhang X, Jiang M, Niu W, Xu B, Zhang C, Yang M et al. CircPRKD3-loaded exosomes concomitantly elicit tumor growth inhibition and glioblastoma microenvironment remodeling via inhibiting STAT3 signaling. Neurooncology. 2025:noaf019. https:\/\/doi.org\/10.1093\/neuonc\/noaf019.","DOI":"10.1093\/neuonc\/noaf019"},{"key":"3459_CR107","doi-asserted-by":"publisher","first-page":"641469","DOI":"10.3389\/fcell.2021.641469","volume":"9","author":"P Wu","year":"2021","unstructured":"Wu P, Gao W, Su M, Nice EC, Zhang W, Lin J, et al. Adaptive mechanisms of tumor therapy resistance driven by tumor microenvironment. Front cell Dev biology. 2021;9:641469.","journal-title":"Front cell Dev biology"},{"key":"3459_CR108","doi-asserted-by":"publisher","unstructured":"Pineda E, Domenech M, Hern\u00e1ndez A, Comas S, Bala\u00f1a C. Recurrent glioblastoma: ongoing clinical challenges and future prospects. OncoTargets therapy. 2023:71\u201386. https:\/\/doi.org\/10.2147\/OTT.S366371.","DOI":"10.2147\/OTT.S366371"},{"key":"3459_CR109","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s13287-025-04352-z","volume":"16","author":"J He","year":"2025","unstructured":"He J, Yan X, Hu S. Glioma stem cells: drivers of tumor progression and recurrence. Stem Cell Res Ther. 2025;16:293.","journal-title":"Stem Cell Res Ther"},{"key":"3459_CR110","doi-asserted-by":"publisher","first-page":"4226","DOI":"10.3390\/cancers13164226","volume":"13","author":"AS Basheer","year":"2021","unstructured":"Basheer AS, Abas F, Othman I, Naidu R. Role of inflammatory mediators, macrophages, and neutrophils in glioma maintenance and progression: mechanistic understanding and potential therapeutic applications. Cancers. 2021;13:4226.","journal-title":"Cancers"},{"key":"3459_CR111","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.2217\/fon-2021-0862","volume":"18","author":"Y Chen","year":"2022","unstructured":"Chen Y, Chen Z, Chen R, Fang C, Zhang C, Ji M, et al. Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer. Future Oncol. 2022;18:1757\u201375.","journal-title":"Future Oncol"},{"key":"3459_CR112","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1080\/27694127.2022.2117340","volume":"1","author":"S Bhattacharya","year":"2022","unstructured":"Bhattacharya S, Pfeffer LM, Chaum E. A Novel Combination Therapy Approach Targeting STAT3 and Autophagy in Glioblastoma. Autophagy Rep. 2022;1:385\u20138.","journal-title":"Autophagy Rep"},{"key":"3459_CR113","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.3390\/cancers17233777","volume":"17","author":"V Zoi","year":"2025","unstructured":"Zoi V, Galani V, Sioka C, Alexiou GA, Kyritsis AP. Immunotherapy for Glioblastoma: A Focus on PD-1\/PD-L1 Inhibitors. Cancers. 2025;17:3777.","journal-title":"Cancers"},{"key":"3459_CR114","doi-asserted-by":"publisher","first-page":"1168244","DOI":"10.3389\/fimmu.2023.1168244","volume":"14","author":"Y-F Zeng","year":"2023","unstructured":"Zeng Y-F, Wei X-Y, Guo Q-H, Chen S-Y, Deng S, Liu Z-Z, et al. The efficacy and safety of anti-PD-1\/PD-L1 in treatment of glioma: a single-arm meta-analysis. Front Immunol. 2023;14:1168244.","journal-title":"Front Immunol"},{"key":"3459_CR115","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s11912-023-01417-1","volume":"25","author":"A Pellerino","year":"2023","unstructured":"Pellerino A, Bruno F, Soffietti R, Rud\u00e0 R. Antiangiogenic therapy for malignant brain tumors: does it still matter? Curr Oncol Rep. 2023;25:777\u201385.","journal-title":"Curr Oncol Rep"},{"key":"3459_CR116","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3390\/cells14060407","volume":"14","author":"A Nowacka","year":"2025","unstructured":"Nowacka A, \u015aniegocki M, Smuczy\u0144ski W, Bo\u017ci\u0142ow D, Zi\u00f3\u0142kowska E. Angiogenesis in glioblastoma\u2014treatment approaches. Cells. 2025;14:407.","journal-title":"Cells"},{"key":"3459_CR117","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.cllc.2017.11.003","volume":"19","author":"M Reck","year":"2018","unstructured":"Reck M, Garon EB, Paz-Ares L, Ponce S, Jaime JC, Juan O, et al. Randomized, double-blind phase Ib\/III study of erlotinib with ramucirumab or placebo in previously untreated EGFR-mutant metastatic non\u2013small-cell lung cancer (RELAY): phase Ib results. Clin Lung Cancer. 2018;19:213\u201320. e4.","journal-title":"Clin Lung Cancer"},{"key":"3459_CR118","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/ng.3990","volume":"49","author":"CM Blakely","year":"2017","unstructured":"Blakely CM, Watkins TB, Wu W, Gini B, Chabon JJ, McCoach CE, et al. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet. 2017;49:1693\u2013704.","journal-title":"Nat Genet"},{"key":"3459_CR119","doi-asserted-by":"publisher","first-page":"175883591876374","DOI":"10.1177\/1758835918763744","volume":"10","author":"I Attili","year":"2018","unstructured":"Attili I, Karachaliou N, Bonanno L, Berenguer J, Bracht J, Codony-Servat J, et al. STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer. Therapeutic Adv Med Oncol. 2018;10:1758835918763744.","journal-title":"Therapeutic Adv Med Oncol"},{"key":"3459_CR120","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/s12964-024-01711-w","volume":"22","author":"M Yang","year":"2024","unstructured":"Yang M, Cui M, Sun Y, Liu S, Jiang W. Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance. Cell Communication Signal. 2024;22:338.","journal-title":"Cell Communication Signal"},{"key":"3459_CR121","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s12031-026-02536-7","volume":"76","author":"S Kumari","year":"2026","unstructured":"Kumari S, Misra J, Ravi K, Kumar N, Jha NK, Gupta R. Integrating Molecular Pathology, Tumor Microenvironment, and Novel Therapies to Overcome Resistance in Glioblastoma. J Mol Neurosci. 2026;76:99.","journal-title":"J Mol Neurosci"},{"key":"3459_CR122","doi-asserted-by":"publisher","first-page":"5634","DOI":"10.3390\/ijms26125634","volume":"26","author":"M Meleiro","year":"2025","unstructured":"Meleiro M, Henrique R. Epigenetic Alterations in Glioblastoma Multiforme as Novel Therapeutic Targets: A Scoping Review. Int J Mol Sci. 2025;26:5634.","journal-title":"Int J Mol Sci"},{"key":"3459_CR123","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.3390\/cells14181458","volume":"14","author":"J Chen","year":"2025","unstructured":"Chen J, Wu Q, Berglund AE, Macaulay RJ, Mul\u00e9 JJ, Etame AB. Tumor-associated macrophages in glioblastoma: mechanisms of tumor progression and therapeutic strategies. Cells. 2025;14:1458.","journal-title":"Cells"},{"key":"3459_CR124","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3390\/cancers15030830","volume":"15","author":"AB Zhang","year":"2023","unstructured":"Zhang AB, Mozaffari K, Aguirre B, Li V, Kubba R, Desai NC, et al. Exploring the past, present, and future of anti-angiogenic therapy in glioblastoma. Cancers. 2023;15:830.","journal-title":"Cancers"},{"key":"3459_CR125","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s10238-022-00955-5","volume":"23","author":"SU Khan","year":"2023","unstructured":"Khan SU, Rayees S, Sharma P, Malik F. Targeting redox regulation and autophagy systems in cancer stem cells. Clin Experimental Med. 2023;23:1405\u201323.","journal-title":"Clin Experimental Med"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03459-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03459-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03459-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:02:15Z","timestamp":1791464535000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03459-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":125,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["3459"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03459-4","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"327"}}